Meet the management and board of the 21st century brewers.
Simon WaddingtonChief Executive OfficerView Bio
Chief Executive Officer
Simon was appointed CEO in July 2017. He previously was COO (Products) and CEO of Evolva Inc. Before that he was President and CEO of Abunda which was acquired by Evolva in July 2011. He spent more than a decade as a venture capitalist. He was a managing partner at Poly-Technos Venture Partners, based in Munich, Germany, where he led and supported investments in numerous life science and advanced materials-related companies in Europe, Israel and the US. Prior to that, he started and ran Monsanto’s European corporate venturing activities from Brussels, Belgium, where he sourced and supported innovations across the medical, agricultural, nutrition, health care services and advanced materials sectors. Before that he was Product Development Manager for Zeneca’s biopolymers business, which pioneered the fermentation-based production of bio-degradable polymers from renewable feedstocks. Prior to that, he served as a Senior Research Scientist for ICI specialising in surface and interface science. Simon earned his PhD in Physics from Liverpool University and his MBA from the Harvard Business School.
Oliver WalkerChief Financial OfficerView Bio
Chief Financial Officer
Oliver Walker is a finance executive with more than 20 years of experience in international companies, both listed and privately-held, and was active in high growth industries and mature industries alike. Amongst other senior positions he was previously CFO of several leading Life Sciences companies, including Sivantos (Singapore), Nobel Biocare, Sonova and Stratec (all Switzerland). His experience covers all aspects of finance including M&A, capital market transactions, treasury, reporting and fundraising. Oliver has an MSc in Business Administration & Economics at the University of Berne.
Scott FabroChief Commercial OfficerView Bio
Chief Commercial Officer
Scott has broad executive experience in various marketing functions in the food industry including ACH Foods, Kerry and Cargill. Before joining Evolva he was Vice-President of ingredient sales at Sweet Harvest Foods. He has extensive knowledge and 27 years of experience in the area of value-added ingredients. At most of his previous postings, Scott’s responsibilities spanned strategy development, R&D, commercialisation as well overall P&L responsibility.
Scott’s career highlights include leading ACH’s Humko Specialty Powders Division, where he commercialised NutriSperse® nutritional beverage bases and a unique vitamin E. At Kerry he successfully led the Aromont® culinary, nutritional lipids and specialty powders businesses. While at Cargill he led the commercial strategy for Omega- 3, Beta-glucans, Truvia® ingredient stevia, ViaTech® stevia and led the commercial strategy on EverSweet™ with Evolva.
Scott Fabro has a Bachelor’s degree in Marketing from the University of Wisconsin-River Falls. He doesn’t hold any relevant Board mandates outside Evolva.
Gerard HoetmerChairmanView Bio
Gerard spent the first 25 years of his career in various units within the multinational consumer goods company Unilever. Starting in engineering and production management, his responsibilities increased to include logistics, supply chain and commercial.
In his first general management steps during his Unilever career he was responsible for Sales and Marketing and later as CEO of Loders Croklaan, a speciality food ingredient company. In 2000, Mr Hoetmer took on the position as Senior Vice President Supply Chain Unilever Foods and Member of the Unilever Foods Executive Board, generating a turnover of EUR 27 billion. In 2005 he left Unilever to join Corbion N.V. (formerly CSM N.V.), a Dutch Euronext-listed group, as CEO. While at Corbion Mr Hoetmer oversaw the company’s transformation from a broad food and food ingredients manufacturer to a focused industrial biotech company delivering bio-based products made from renewable resources. In 2014, Corbion generated revenue of EUR 770 million and counted nearly 2,000 employees. Mr Hoetmer retired from this function in 2014. He has a Master degree in Mechanical Engineering from Delft University in the Netherlands. He is chairman of the boards of Devro plc (UK listed), AON Holdings B.V. (Netherlands, not listed) as well as Dutch football club Feyenoord (not listed).
Ganesh KishoreBoardView Bio
Kish has been a member of the Board of Directors since May 2011. He received his PhD in biochemistry from the Indian Institute of Science after which he pursued postdoctoral research in chemistry and biology at the University of Texas at Austin. In 1980, he joined Monsanto where he held senior positions in the areas of biotechnology and in the Nutrition and Consumer Products division. During his tenure at Monsanto he was involved in the development of major products such as Aspartame (the active ingredient of several major sweetener products) as well as a key agricultural crop protection technology. Kish joined DuPont in 2002 as the Chief Technology Officer for its Agriculture and Nutrition Platform and took over the role of Chief Biotechnology Officer for the company in 2005. He was the CEO of MLSCF (Malaysian Life Sciences Capital Fund), which is a shareholder in Evolva. His other Board mandates include Kaiima, Greenlight Biosciences, Provivi, Sentinext (Chair) and MOgene LC. He also serves on the Board of several academic institutions and as an advisor to a few agricultural companies.
Jutta HeimBoardView Bio
Jutta worked for more than 20 years at Ciba-Geigy/Novartis (CH and US). At Novartis, she was involved in the successful development and launch of anti-thrombotic and fibrinolytic products. She established Novartis’ molecular genetics department in oncology, became Novartis’ Senior Scientific Expert in Molecular Biology and a member of the Research Management Board. She completed her career at Novartis heading the Novartis Lead Discovery Center with worldwide responsibility. From 2004 to 2009, Jutta served as CSO at Basilea Pharmaceutica Ltd., a Swiss biopharmaceutical company focusing on anti-infectives, inflammation and oncology. From 2009 to 2013, she served as CTO and CSO at Evolva. She received a PhD from the University of Tübingen in 1981 and holds a professorship in Biotechnology at the Biocenter of the University of Basel. Dr. Heim is a member of the Advisory Board of “Stiftung für Wissenschaftliche Forschung Universität Zürich” and a Board member of Nuevolution A/S. She also serves as chair of the scientific advisory committee of GARDP/DNDi (Global Antibiotic R&D Partnership / Drugs for Neglected Diseases initiative). Moreover, she is on the Board/Scientific Expert Panel of several academic institutions.
Martin GertschBoardView Bio
Martin has been a member of the Board of Directors since May 2012. He is an experienced Board Member and Financial Advisor in the life science industry. He was CFO of Acino Pharma AG where he stepped down in January 2014 after its going private. He is former Vice-President Head of Finance EMEA at DePuySynthes and former Chief Financial and Chief Operating Officer of Delenex Therapeutics and ESBATech, two privately held biotech companies. From 2002 to the beginning of 2006, he was Chief Financial Officer of Straumann, which he had joined in 1997 as head of group controlling and reporting. Between 1986 and 1997, Martin was an audit engagement manager at PricewaterhouseCoopers, Basel, Switzerland. He is a Swiss certified fiduciary and Swiss certified public accountant. He has also completed several executive-level development programmes at IMD (International Institute for Management Development) in Lausanne, Switzerland. Martin serves as Vice-Chairman of the Board and chairman of the audit commitee of Santhera Pharmaceuticals and as Board Member of the University Center of Dentistry, Basel (UZB). He is also Chairman of the Board of two diagnostic start-up companies.
Stuart StrathdeeBoardView Bio
Stuart has been a member of the Board since May 2011. Having completed his PhD in Applied Physics, he joined Tate & Lyle plc in 1977 as a management trainee. He retired from the company in July 2009, having served on the main Board as an Executive Director in various roles for 14 years. During his time at Tate & Lyle, Stuart held a variety of senior management positions including Group Treasurer, Managing Director of both United Molasses and Tate & Lyle’s International Division and was Corporate Development Director reporting to the Chief Executive Officer from July 2003. Leadership highlights include: the development of Tate & Lyle’s sucralose ingredient business; creation of Vietnam’s leading sugar business; the public takeover of Australia’s largest sugar farming company; creation of a joint venture to construct the Middle East’s largest sugar refinery; the acquisition of publicly listed Zambia Sugar Company, now Africa’s leading sugar milling company. Stuart has a PhD in Atomic and Molecular Physics from Queens University Belfast. He is a member of the Board of James Finlay Ltd.
Thomas VidebaekBoardView Bio
Thomas has been a member of the Board of Directors since May 2012. He has been a member of the Novozymes Executive Management Group since September 2007, currently responsible for corporate business development. Thomas joined Novo Nordisk as a chemist in 1988 and worked in various positions in the Textiles and Starch divisions, both in Denmark and in the US. In 1996, he assumed responsibility for Food and Feed enzymes and was appointed Director for Strategic Marketing, Food and Feed enzymes. At the end of 1998, Thomas was appointed General Manager for Novozymes Switzerland and also Vice-President for Cereal Food and Beverage Marketing. He returned to Denmark in 2003 and became Vice-President for Supply Chain Operations where he was responsible for establishing a global organisation in charge of the supply chain at Novozymes. Thomas holds a Master of Chemical Engineering from DTU, Dept. of Nutrition and Biochemistry, Copenhagen 1986, and a PhD from DTU in 1990. He also holds a BCom (International Business) from the Copenhagen Business School (1992). He is Vice Chairman of the Board of Albumedix A/S.